MovDisordV3, Main, Merge, bibRecord, 005341

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease

Identifieur interne : 005341 ( Main/Merge ); précédent : 005340; suivant : 005342

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease

Auteurs : William Bara-Jimenez [États-Unis] ; Francesco Bibbiani [États-Unis] ; Michael J. Morris [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Maral M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0444021

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Dyskinésie, Stimulant sérotoninergique, Stade avancé, Récepteur sérotoninergique 5-HT1A, Sérotonine, Dopamine, Lévodopa.

English descriptors

KwdEn :
- 5-HT1A Serotonine receptor, Advanced stage, Dopamine, Dyskinesia, Levodopa, Nervous system diseases, Parkinson disease, Serotonin, Serotonin agonist.

Abstract

Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5-HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. To evaluate this hypothesis, effects of a selective 5-HT1A agonist, sarizotan, given orally at 2 and 5 mg twice daily to 18 relatively advanced parkinsonian patients, were compared with baseline placebo function during a 3-week, double-blind, placebo-controlled, proof-of-concept study. Sarizotan alone or with intravenous levodopa had no effect on parkinsonian severity. But at safe and tolerable doses, sarizotan coadministration reduced levodopa-induced dyskinesias and prolonged its antiparkinsonian response (P ≤ 0.05). Under the conditions of this study, our findings suggest that 5-HT1A receptor stimulation in levodopa-treated parkinsonian patients can modulate striatal dopaminergic function and that 5-HT1A agonists may be useful as levodopa adjuvants in the treatment of PD.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001E12
to stream PascalFrancis, to step Curation: 000F09
to stream PascalFrancis, to step Checkpoint: 001E63

Links to Exploration step

Pascal:05-0444021

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease</title>
<author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J." last="Morris">Michael J. Morris</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M." last="Mouradian">Maral M. Mouradian</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0444021</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0444021 INIST</idno>
<idno type="RBID">Pascal:05-0444021</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E12</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F09</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001E63</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Bara Jimenez W:effects:of:serotonin</idno>
<idno type="wicri:Area/Main/Merge">005341</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease</title>
<author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J." last="Morris">Michael J. Morris</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M." last="Mouradian">Maral M. Mouradian</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT1A Serotonine receptor</term>
<term>Advanced stage</term>
<term>Dopamine</term>
<term>Dyskinesia</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Serotonin</term>
<term>Serotonin agonist</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Stimulant sérotoninergique</term>
<term>Stade avancé</term>
<term>Récepteur sérotoninergique 5-HT1A</term>
<term>Sérotonine</term>
<term>Dopamine</term>
<term>Lévodopa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Intermittent stimulation of striatal dopaminergic receptors seems to contribute to motor dysfunction in advanced Parkinson's disease (PD). With severe dopaminergic denervation, exogenous levodopa is largely decarboxylated to dopamine in serotonergic terminals. If 5-HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. To evaluate this hypothesis, effects of a selective 5-HT1A agonist, sarizotan, given orally at 2 and 5 mg twice daily to 18 relatively advanced parkinsonian patients, were compared with baseline placebo function during a 3-week, double-blind, placebo-controlled, proof-of-concept study. Sarizotan alone or with intravenous levodopa had no effect on parkinsonian severity. But at safe and tolerable doses, sarizotan coadministration reduced levodopa-induced dyskinesias and prolonged its antiparkinsonian response (P ≤ 0.05). Under the conditions of this study, our findings suggest that 5-HT1A receptor stimulation in levodopa-treated parkinsonian patients can modulate striatal dopaminergic function and that 5-HT1A agonists may be useful as levodopa adjuvants in the treatment of PD.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
</region>
<name sortKey="Bibbiani, Francesco" sort="Bibbiani, Francesco" uniqKey="Bibbiani F" first="Francesco" last="Bibbiani">Francesco Bibbiani</name>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<name sortKey="Dimitrova, Tzvetelina" sort="Dimitrova, Tzvetelina" uniqKey="Dimitrova T" first="Tzvetelina" last="Dimitrova">Tzvetelina Dimitrova</name>
<name sortKey="Morris, Michael J" sort="Morris, Michael J" uniqKey="Morris M" first="Michael J." last="Morris">Michael J. Morris</name>
<name sortKey="Mouradian, Maral M" sort="Mouradian, Maral M" uniqKey="Mouradian M" first="Maral M." last="Mouradian">Maral M. Mouradian</name>
<name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005341 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005341 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:05-0444021
   |texte=   Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri